

























Monitoring of 30 marker candidates in
early Parkinson disease as progression
markers
ABSTRACT
Objective: This was a longitudinal single-center cohort study to comprehensively explore multi-
modal progression markers for Parkinson disease (PD) in patients with recently diagnosed PD
(n 5 123) and age-matched, neurologically healthy controls (HC; n 5 106).
Methods: Thirty tests at baseline and after 24 months covered nonmotor symptoms (NMS), cog-
nitive function, and REM sleep behavior disorder (RBD) by polysomnography (PSG), voxel-based
morphometry (VBM) of the brain by MRI, and CSF markers. Linear mixed-effect models were used
to estimate differences of rates of change and to provide standardized effect sizes (d) with 95%
confidence intervals (CI).
Results: A composite panel of 10 informative markers was identified. Significant relative worsen-
ing (PD vs HC) was seen with the following markers: the Unified Parkinson’s Disease Rating Scale I
(d 0.39; CI 0.09–0.70), the Autonomic Scale for Outcomes in Parkinson’s Disease (d 0.25; CI
0.06–0.46), the Epworth Sleepiness Scale (d 0.47; CI 0.24–0.71), the RBD Screening Ques-
tionnaire (d 0.44; CI 0.25–0.64), and RBD by PSG (d 0.37; CI 0.19–0.55) as well as VBM units of
cortical gray matter (d 20.2; CI 20.3 to 20.09) and hippocampus (d 20.15; CI 20.27 to 20.03).
Markers with a relative improvement included the Nonmotor Symptom (Severity) Scale (d 20.19; CI
20.36 to 20.02) and 2 depression scales (Beck Depression Inventory d 20.18; CI 20.36 to 0;
Montgomery-Åsberg Depression Rating Scale d 20.26; CI 20.47 to 20.04). Unexpectedly, cogni-
tive measures and select laboratory markers were not significantly changed in PD vs HC participants.
Conclusions: Current CSF biomarkers and cognitive scales do not represent useful progression
markers. However, sleep and imaging measures, and to some extent NMS, assessed using ade-
quate scales, may be more informative markers to quantify progression. Neurology®
2016;87:168–177
GLOSSARY
24FU 5 24 months follow-up; a-syn 5 a-synuclein; AD 5 Alzheimer disease; BDI 5 Beck Depression Inventory; BL 5
baseline; DeNoPa 5 de novo Parkinson; ESS5 Epworth Sleepiness Scale; HC5 healthy control; LED 5 levodopa equivalent
dosage;MADRS5Montgomery-Åsberg Depression Rating Scale;MDS5Movement Disorder Society;MMSE5Mini-Mental
State Examination; MoCA 5 Montreal Cognitive Assessment Test; NMS 5 nonmotor signs; NMSS 5 Nonmotor Symptom
Scale; p-tau5 tau protein phosphorylated at threonine 181; PD5 Parkinson disease; PSG5 polysomnography; RBD5 REM
sleep behavior disorder; RBD-SQ5 REM Sleep Behavior Disorder Screening Questionnaire; Scopa-AUT5 Autonomic Scale
for Outcomes in Parkinson’s Disease; t-tau 5 total tau protein; UPDRS 5 Unified Parkinson’s Disease Rating Scale; VBM 5
voxel-based morphometry.
One of the great challenges in Parkinson disease (PD) therapeutics is the definition of clinically
meaningful endpoints that measure progression, or lack thereof.1 To date, numerous clinical
trials with putative neuroprotective agents have yielded negative results.2–4 It remains unclear
whether trial design or the agent tested, or both, are the reasons for past failures.
Currently, several parameters are typically selected as endpoints for use in symptomatic and
neuroprotective treatment trials, e.g., the Unified Parkinson’s Disease Rating Scale (UPDRS),
quality of life measurements,5 or the “need for levodopa therapy.”2
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Reports of selective, longitudinal investiga-
tions of nonmotor signs (NMS),6–8 neuroi-
maging, and laboratory analyses9 have been
previously published as potential markers of
progression.10 These investigations were
largely conducted in smaller cohorts and
focused on single symptoms/measures and fre-
quently relied on more advanced PD cases,
and lacked age-matched healthy controls.
The de novo Parkinson (DeNoPa) cohort
represents a prospective, longitudinal, single-
center, observational study of participants
with de novo PD and matched neurologically
healthy controls (HC). The study’s aim is to
improve early diagnosis and to assess proper
progression markers, scored at baseline with
biannual follow-up.11
We hypothesized that a composite panel of
multimodal progression markers covering
overall NMS, cognitive measures, sleep, imag-
ing, and CSF indices would be instructive in
understanding the natural history of early
PD, and to thereby delineate specific and sen-
sitive outcome measures for future interven-
tion trials. To this end, we applied the same
panel of tests to a group of HC to separate
PD changes from the process of normal aging.
METHODS Study participants. Longitudinal data were col-
lected at baseline (BL) and at 24 months follow-up (24FU).
Detailed inclusion criteria have been described previously11 and
are summarized in appendix e-1 on the Neurology® Web site at
Neurology.org.
After BL assessments, all patients started dopaminergic ther-
apy according to accepted guidelines12 with stable medication
until the 24FU visit. The levodopa equivalent dosage (LED) at
24FU was determined as described.13 The clinical diagnosis was
reassessed in the on state for all patients at 24FU by consensus of
2 teams of independent neurologists (C.T./F.S.-D. and B.M./J.
E.; for details, see appendix e-1).
Standard protocol approvals, registrations, and patient
consents. We received approval from the ethical standards com-
mittee on human experimentation (Landesärztekammer Frank-
furt) for all experiments using human participants. Written
informed consent was obtained from all study participants (con-
sent for research).
Procedures. Protocols, data collection, and data/sample storage
have been described previously.11 Briefly, our approach is of an
exploratory nature. We examined longitudinal assessments using
validated and published tools: NMS were the most relevant diag-
nostic tests in DeNoPa11 and were also investigated longitudinally
by means of the Movement Disorder Society (MDS) UPDRS
part I,14 the NMS Questionnaire, the Nonmotor Symptom Scale
(NMSS), and the Autonomic Scale for Outcomes in Parkinson’s
Disease (Scopa-AUT). The PD Questionnaire, which has been
the primary endpoint in randomized studies,5 was used together
with assessment of depression by the self-reported Beck
Depression Inventory (BDI) and the Montgomery-Åsberg
Depression Rating Scale (MADRS). Cognition was tested with
the Mini-Mental State Examination (MMSE), the Montreal
Cognitive Assessment Test (MoCA), and the Clock Drawing
Test. Further tests for different cognitive domains are given in
appendix e-1. Sleep was assessed using the Parkinson’s Disease
Sleep Scale, the Epworth Sleepiness Scale (ESS), and the REM
Sleep Behavior Disorder (RBD) Screening Questionnaire (RBD-
SQ). In addition, we performed video-supported polysomnography
(PSG) to classify RBD. Voxel-based morphometry (VBM) of gray
matter and hippocampus by 1.5T volumetric MRI was included
because significant atrophy has been described in correlation with
PD progression and cognitive decline.15 We also investigated serum
urate.16 We tested known CSF markers that have been previously
discussed as potential diagnostic markers of PD state or its
progression, including total a-synuclein (a-syn), b-amyloid 1-42,
total and phosphorylated tau protein (t-tau and p-tau), as well as
neurofilament light chain proteins.17 See appendix e-1 for
experimental details.
Statistical analysis. We used linear mixed-effect models to
identify differences in the rates of change in selected markers
between PD and controls. For each marker, we estimated a
random intercept model including group (PD vs HC), time (BL vs
24FU), and their interaction as predictors. Models were estimated
using restricted maximum likelihood estimation, taking into
account all available data points at BL and 24FU. Differential
change in PD is apparent in a significant group multiplied by the
time interaction. We present model-based effect sizes for
differential change, standardized by the observed SD in the PD
group at baseline.18 Significance testing was based on 95%
confidence intervals using parametric bootstrap with 2,000 resamples.
In addition, we explored whether changes in individual markers
were influenced by selected BL characteristics. To this end, we con-
ducted robust multiple regression analyses in the PD sample pre-
dicting 24FU scores of individual markers (while controlling for
respective BL scores) from LED and dopamine agonists at 24FU
and selected sociodemographic and clinical factors at BL. Robust
regression was used to deal with non-normality (e.g., outliers) in
the distribution of markers.19 All analyses were carried out with
the statistical platform R,20 using the package lme4 for linear mixed
models and robustbase for robust regressions.
We did not correct for multiple testing since our approach
was of an exploratory nature (see also the Discussion and appen-
dix e-1).21 However, marker candidates were chosen according to
their clinical relevance and following a review of the literature.
RESULTS Of the 269 recruited participants, 254
(94%) underwent follow-up assessments (147 PD and
107 HC). Four patients and 2 controls died before
24FU. Reassessment of the clinical working diagnosis
led to the identification of a distinct neurologic
disorder in 24 (16%) patients shown in figure e-1.
The reassessment of our previously described panel of
diagnostic markers11 in the remaining 123 patients
with PD and 106 HC at BL remained significant.
The demographics, motor characteristics, and de-
tails of dopaminergic treatment at 24FU are shown in
table 1.
Panel of progression markers. Table 2 list the results of
30 tests performed in the entire DeNoPa cohort,
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which we used as surrogate markers for PD and its
progression. Ten of the 30 markers showed statisti-
cally significant rates of change relative to HC over
the 2-year observational period, mainly in the
categories of NMS, depression, sleep, and imaging
(table 2 and figures 1–3).
Clinical measures. Nonmotor symptoms significantly
worsened in PD vs HC as assessed by the MDS-
UPDRS I score (table 2 and figure 1A). The
worsening of autonomic features relative to controls
was reflected by a statistically significant increase in the
Scopa-AUT scores (table 2 and figure 1D). This
increase was mainly driven by an increase in
cardiovascular items of the Scopa-AUT (data not
shown). In contrast, the severity score for NMS (by
NMSS) showed improvement in relation to controls
(table 2 and figure 1C). Assessment of depression
showed a significant improvement in the self-
reported BDI and investigator-rated MADRS (table
2 and figure 1, F and G).
Most of our preselected cognitive measures were
worse in PD than in controls during follow-up. Inter-
estingly, slopes were parallel for PD and HC,
revealing no significant incremental changes in PD
over controls in single tests (table 2). Also, the tests
for executive function showed a parallel (and nonsig-
nificant) decrease for both groups.
Excessive daytime sleepiness, as assessed by the
ESS, significantly worsened with PD progression
compared to controls. RBD significantly increased
for the PD group by questionnaire at follow-up, while
it decreased in HC (table 2 and figure 2, A–C).
Technical investigations. PSG also showed a significant
increase of the prevalence of RBD in patients with
PD while in HC the prevalence increased only
slightly, as expected, with increasing age (table 2
and figure 2D). The severity of RBD by RBD severity
score22 in PD did not differ between baseline and
24FU (data not shown).
Volumetric imaging measures of cortical and hip-
pocampal structures by MRI decreased significantly
at 24FU in patients with PD (figure 3, A and B),
which was not associated with age, PD phenotype
(table e-1), or changes in cognitive measures (data
not shown). Statistical parametric maps and change
plots of VBM measures of cortical and hippocampal
Table 1 Demographic characteristics, motor symptoms, and information on dopaminergic medication of patients with de novo Parkinson
disease (PD, n 5 123) and healthy controls (HC, n 5 106) at baseline (BL) and 24 months follow-up (24FU)
PD (n 5 123) HC (n 5 106)
p Value, BL
PD vs HCBL 24FU BL 24FU
Demographics
Age, y 63.7 (9.5, 40–84) 65.8 (9.4, 42–86) 64.6 (6.8, 44–84) 66.7 (6.8, 44–86) .0.05
Male/female, % 79/44 (64/36) 63/43 (59/41) .0.05
Follow-up time, mo 25.3 (2.6, 18–34) 25.5 (1.6, 22–31) .0.05
Motor symptoms
Duration of first motor symptom
until diagnosis, mo
25.2 (36.6, 2–240) — — —
MDS-UPDRS II 8.1 (4.84, 0–29) 9.7 (5.6, 0–28) 0.2 (0.5, 0–2) 1.0 (1.5, 0–9) ,0.001
MDS-UPDRS III 21.5 (11.6, 3–66) 23.6 (13.2, 1–64) 0.6 (1.4, 0–6) 1.5 (2.6, 0–12) ,0.001
MDS-UPDRS total scorea 35.7 (17.7, 7–88) 43.0 (22.8, 3–109) 3.3 (3.1, 0–15) 6.6 (6.9, 0–37) ,0.001
Hoehn & Yahr stage 1.8 (0.6, 1–3) 1.9 (0.7, 1–4) — — —
Dopaminergic medication
Levodopa 0 67 (54) — — —
Dopamine agonists 0 86 (70) — — —
Pramipexole 0 56 (46) — — —
Ropinirole 0 9 (7) — — —
Piribedil 0 13 (11) — — —
Rotigotine 0 6 (5) — — —
MAOB inhibitor 0 86 (70) — — —
Total levodopa equivalent dosage 0 372 (243, 0–1,565) — — —
Abbreviations: MAOB 5 monoamine oxidase B; MDS-UPDRS 5 Movement Disorder Society Unified Parkinson’s Disease Rating Scale.
Data are mean (SD, range) or n (%). Age and sex were part of the frequency matching.
aWe identified 68 (55%) tremor-dominant, 14 (11%) intermediate, and 41 (33%) postural instability and gait disorder subtypes in our patients.
170 Neurology 87 July 12, 2016
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.







differenceHC baseline PD baseline difference HC change PD change difference
BL 24FU Effect 95% CI Effect 95% CI Effect 95% CI Effect 95% CI Effect 95% CI
Nonmotor symptoms
MDS-UPDRS Ia,b 229 228 4.27 2.57 1.66 to 3.51 3.58 2.31 to 4.83 1.61 0.64 to 2.55 1.65 0.38 to 2.97 0.39 0.09 to 0.7
NMS Questionnaire 229 228 4.03 3.78 3.12 to 4.53 3.77 2.70 to 4.65 0.25 20.32 to 0.79 0.45 20.24 to 1.15 0.11 20.06 to 0.29
NMS Scalea,b 227 228 30.89 13.04 8.61 to 17.37 23.92 18.07 to 29.86 1.90 22.34 to 5.61 25.99 211.20 to 20.62 20.19 20.36 to 20.02
Assessment of autonomic
dysfunction (Scopa-AUT)a,b
229 229 6.7 8.25 6.97 to 9.52 4.45 2.71 to 6.06 0.48 20.52 to 1.4 1.69 0.38 to 3.07 0.25 0.06 to 0.46
Depression and impairment of quality
of life
Parkinson’s Disease Questionnaire 229 229 18.62 9.42 6.14 to 12.48 18.88 14.68 to 22.97 1.18 21.18 to 3.58 2.19 21.05 to 5.49 0.12 20.06 to 0.29
Beck Depression Inventorya,b 229 229 6.67 3.4 2.4 to 4.45 5.59 4.19 to 6.99 0.19 20.7 to 1.07 21.22 22.44 to 20.02 20.18 20.36 to 0
Montgomery-Åsberg Depression
Rating Scalea,b
227 225 7.23 4.05 2.87 to 5.17 4.89 3.32 to 6.47 21.88 23.09 to 20.67 21.87 23.41 to 20.31 20.26 20.47 to 20.04
Cognitive tests
Screening instruments
Mini-Mental State Examination 226 225 1.29 28.87 28.6 to 29.13 20.28 20.61 to 0.07 20.33 20.63 to 20.03 20.07 20.5 to 0.32 20.06 20.38 to 0.25
Montreal Cognitive Assessment 188 226 3 26.01 25.42 to 26.56 21.03 21.82 to 20.26 20.45 20.97 to 0.11 20.3 21.07 to 0.44 20.1 20.36 to 0.15
Clock Drawing Test 227 225 0.93 1.27 1.12 to 1.43 0.35 0.14 to 0.57 0.12 20.05 to 0.29 20.15 20.37 to 0.07 20.16 20.4 to 0.08
Domain-specific tests
Attention and working memory
Trail-Making test (B/A) 223 222 0.89 2.72 2.5 to 2.94 0.02 20.28 to 0.32 0.2 20.03 to 0.44 0.05 20.27 to 0.35 0.06 20.31 to 0.4
Digit Span Backward 228 226 1.78 6.12 5.77 to 6.47 20.51 21 to 20.04 20.15 20.44 to 0.13 20.06 20.47 to 0.34 20.04 20.27 to 0.19
Executive function
Verbal Fluency (RWT) 224 222 5.61 19.17 18.06 to 20.28 22.61 24.15 to 21.05 0.64 20.27 to 1.54 20.02 21.26 to 1.2 0 20.22 to 0.21
Stroop Test 218 221 26.07 79.31 74.84 to 83.72 17.35 11.36 to 23.2 22.06 25.1 to 1.1 20.72 25.18 to 3.78 20.03 20.2 to 0.15
Language
Similarities (WIE) 227 224 5.65 24.8 23.73 to 25.8 21.76 23.14 to 20.37 0.65 20.13 to 1.41 20.05 21.13 to 0.95 20.01 20.2 to 0.17
Memory
Verbal Learning and Memory Test 220 224 4.8 10.02 9.13 to 10.94 20.93 22.25 to 0.28 20.25 21.08 to 0.62 20.21 21.33 to 0.95 20.04 20.28 to 0.2
























differenceHC baseline PD baseline difference HC change PD change difference
BL 24FU Effect 95% CI Effect 95% CI Effect 95% CI Effect 95% CI Effect 95% CI
Social cognition
Social cognition (MASC) 221 218 5.98 28.16 26.87 to 29.33 21.92 23.49 to 20.3 0.4 20.46 to 1.31 20.86 22.09 to 0.31 20.14 20.35 to 0.05
Sleep/RBD and PSG
Parkinson’s Disease Sleep Scale 228 228 8.79 10.17 8.58 to 11.77 5.34 3.25 to 7.54 0.2 21.06 to 1.48 0.94 20.77 to 2.71 0.11 20.09 to 0.31
Epworth Sleepiness Scalea,b 228 229 3.93 6.93 6.18 to 7.68 0.42 20.58 to 1.43 20.59 21.27 to 0.08 1.83 0.93 to 2.78 0.47 0.24 to 0.71
RBD Screening Questionnairea,b 229 229 2.86 2.29 1.81 to 2.81 1.24 0.58 to 1.93 20.18 20.59 to 0.2 1.27 0.72 to 1.82 0.44 0.25 to 0.64
RBD by PSGa,b 228 215 0.44 0.02 20.05 to 0.09 0.24 0.14 to 0.33 0.02 20.04 to 0.08 0.16 0.08 to 0.24 0.37 0.19 to 0.55
MRI and voxel-based morphometry
Gray matter volume (VBM), %a,b 175 175 2.31 43.38 43.02 to 43.77 20.35 20.84 to 0.14 20.14 20.31 to 0.02 20.46 20.71 to 20.22 20.2 20.3 to 20.09
Hippocampal volume (VBM), %a,b 171 171 2.61 64.54 64.10 to 65.01 20.78 21.46 to 20.17 20.24 20.46 to 20.03 20.38 20.69 to 20.07 20.15 20.27 to 20.03
Laboratory marker in serum or CSFc
Serum uric acid, mg/dL 229 229 1.38 5.53 5.27 to 5.79 20.25 20.61 to 0.11 0.13 20.04 to 0.30 0.15 20.09 to 0.40 0.11 20.06 to 0.29
CSF a-synuclein, pg/mL 136 73 594.93 1,632.36 1,473.91 to 1,793.23 2198.55 2408.58 to 12.27 255.39 2156.85 to 44.03 79.14 255.37 to 205.90 0.13 20.09 to 0.35
CSF b-amyloid 1–42, pg/mL 135 75 204.68 875.99 816.72 to 932.52 217.94 295.44 to 62.44 10.30 237.57 to 58.44 37.77 224.18 to 97.36 0.18 20.12 to 0.48
CSF total-tau protein, pg/mL 135 75 103.03 271.26 236.49 to 304.84 240.03 285.32 to 3.33 4.40 233.65 to 43.23 33.67 216.38 to 84.38 0.33 20.16 to 0.82
CSF phosphorylated tau protein,
pg/mL
128 73 14.47 47.66 43.34 to 52.21 26.19 212.10 to 20.59 21.68 24.16 to 0.77 1.32 21.82 to 4.38 0.09 20.13 to 0.3
CSF neurofilament light chain, pg/mL 133 74 477.38 614.40 502.11 to 736.21 102.75 253.64 to 255.38 148.89 64.79 to 231.18 237.84 2145.49 to 79.78 20.08 20.3 to 0.17
Abbreviations: 24FU 5 24 months follow-up; BL5 baseline; CI 5 confidence interval; HC 5 healthy control; MASC 5Movie for the Assessment of Social Cognition; NMS 5 nonmotor signs; PD 5 Parkinson disease;
PSG 5 polysomnography; RBD 5 REM sleep behavior disorder; RWT 5 Regensburger Wortflüssigkeitstest; WIE 5 Wechsler Intelligenztest für Erwachsene; Scopa-AUT 5 Autonomic Scale for Outcomes in
Parkinson’s Disease; MDS-UPDRS 5 Unified Parkinson’s Disease Rating Scale; VBM 5 voxel-based morphometry.
All estimates are unadjusted except for the neuroimaging measures, which are adjusted for age, sex, and total intracranial volume. Columns on the right indicate standardized effect size.
ap , 0.05.
b The composite panel out of 10 measures as suggested.
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volume for both groups indicate regions where atro-
phy rates differed significantly in patients with PD vs
controls (figure 3, C and D).
Serum uric acid levels did not significantly differ
between PD and HC at baseline and at 24FU. Total
CSF a-syn levels were lower in patients with PD
compared to HC at BL and 24FU, but the rates of
changes were not significant. Furthermore, a nonsig-
nificant increase in CSF for t-tau was observed (figure
e-2). Results for CSF ratios were not significantly
altered (data not shown).
Predictors of change during 24-month observation.Mul-
tiple regression analysis in the PD group, which tested
the joint statistical influence of 8 potentially con-
founding factors, showed only 24 (10%) significant
effects regarding changes within the panel of 30 inves-
tigated markers (table e-1). For example, the presence
of RBD at BL indicated worse cognitive decline on
MoCA. The LED, as another surrogate marker for
clinical severity, was significantly associated with
decreased cognitive function (by the memory screen-
ing test MMSE and the attention/working memory
test Digit Span Backward) and increasing RBD as
well as serum uric acid. The intake of dopamine ago-
nists was associated with improvement of depression
(BDI), worse performance on the memory task Ver-
bal Learning and Memory Test, and increase on
CSF p-tau but no other marker.
DISCUSSION We performed a 2-year follow-up
investigation on clinical measures and biomarkers
through clinical and technical assessment, including
PSG, MRI, and serum/CSF measures in the largest
single-center cohort of 123 clinically diagnosed
early PD participants and 106 matched healthy
controls. Overall, we found that 20 of 30 tests
showed no statistically significant and no specific
progression in our DeNoPa patients. The remaining
10 markers showed statistically significant changes
reflecting either progression in PD or change due to
treatment or both when compared to controls: these
encompassed increasing sleep disturbances and
worsening of NMS, whereas NMS severity (NMSS)
and depression (by MADRS and BDI) improved.
Regarding imaging markers, general gray matter
Figure 1 Longitudinal changes in nonmotor symptoms (NMS), impaired quality of life (QoL), and depression
Estimated means and 95% confidence intervals of Movement Disorder Society–Unified Parkinson’s Disease Rating Scale I (MDS-UPDRS I) (A), NMS
Questionnaire (NMSQuest) (B), NMS Severity Scale (NMSS) (C), Scopa-AUT (D), QoL measure (PDQ-39) (E), and the depression scales: Beck Depression
Inventory (BDI) (F) and Montgomery-Åsberg Depression Rating Scale (MADRS) (G) at baseline (BL) and 2-year follow-up (24FU). Blue line represents healthy
controls (HC); red line represents participants with Parkinson disease (PD). *Significant change in PD vs HC (p , 0.05).
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volume and hippocampal volume specifically and
significantly decreased over the 2-year period.
Clinical measures. Several smaller studies6,7,10 and one
longitudinal study8 have previously suggested the use
of NMS as candidate progression markers. NMS
worsened in PD as measured by the MDS-UPDRS I
in DeNoPa, while the severity of NMS measured by
NMSS improved in our cohort. Autonomic dysfunc-
tion, as assessed by Scopa-AUT, also showed
statistically significant worsening in PD compared to
HC. The only systematic longitudinal investigation on
NMS showed an increase in NMS domains after
24FU, but NMS severity and more specific
autonomic features had not been addressed. Also,
these patients were at different stages of disease and
the majority had received symptomatic treatment
already at BL.8 While the NMS tools cover various
NMS, the MDS-UPDRS I captures a few key
symptoms. Both the NMSS and MDS-UPDRS I
show strong convergent validity.23 The discrepancy of
performance of self-reported vs investigator-reported
NMS in DeNoPa could also be the result of different
sensitivity of scales and questionnaires, and points
towards the need for an improved and widely
standardized assessment of NMS for longitudinal
investigations.
We recorded an improvement of depression in our
patients with PD on 2 independent scales and indi-
vidual differences in improvement were not signifi-
cantly associated with dopaminergic dosage. The
improvement of depression and quality of life in the
early honeymoon phase of PD (generally considered
to represent the first 5–10 years after diagnosis) is
in accordance with other studies,8 and is also related
to dopamine agonists.24
Following analysis of various domains of cognition,
we identified clear differences in cognitive performance
in PD compared to controls (see table 2; PD baseline
differences), but only cross-sectionally and not with
any significant change longitudinally. Most previous
longitudinal studies did not include control groups.25
Therefore previous studies in PD may have overinter-
preted normal cognitive aging and we have thus cor-
rected this deficit in our study design.
RBD and reduced subjective quality of sleep are rec-
ognized inherent symptoms during prodromal and fully
developedmotor PD.26 Daytime sleepiness progressively
worsens in PD, confirming that it may be dependent on
dopaminergic therapy27 or an intrinsic factor of disease
progression. RBD may be a useful marker to monitor
progression of PD either with PSG or with a similar
effect size by a 10-item self-rating questionnaire (RBD-
SQ). The presence of RBD indicates worse cognitive
decline by MoCA, as has been shown previously.28
Technical investigations. To date, DeNoPa comprises
the largest collection and interrogation of longitudi-
nal data of PSG, MRI volumetry, and CSF markers.
Our MRI structural measures showed significant
overall and hippocampal gray matter volume loss in
PD. The hippocampal region was selected, since, ac-
cording to the Braak staging scheme,29 a-syn pathol-
ogy is expected to emerge there before affecting the
neocortex, and hippocampal involvement has been
suggested in PD dementia.30 However, effect sizes
were similar in both measures and correlations with
changes in cognitive markers were nonsignificant in
this early PD cohort (data not shown).
A longitudinal CSF study found increasing tau
and tau/Ab1-42 levels,9 but significantly decreasing
CSF a-syn levels in PD.31 In our study, none of the
CSF markers (or their ratios) that were tested reached
statistical significance for progression. Different
Figure 2 Longitudinal changes in sleep parameters
Estimatedmeans and 95%confidence intervals of the Parkinson’s Disease Sleepiness Scale
(PDSS-2) (A), Epworth Sleepiness Scale (ESS) (B), REM Sleep Behavior Disorder by Ques-
tionnaire (RBD-SQ) (C), and by video-supported polysomnography (PSG) (D), at baseline (BL)
and 2-year follow-up (24FU). Blue line represents healthy controls (HC); red line represents
participants with Parkinson disease (PD). *Significant change in PD vs HC (p , 0.05).
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demographics and sample preparation could account
for this discrepancy. It could also be explained by the
small number (n5 85; 37%) of DeNoPa participants
who consented to serial lumbar puncture (37%) at
24FU. A similarly small annual rate of change in CSF
markers has also been observed in patients with estab-
lished Alzheimer disease (AD). The stability of our
markers in this early stage of motor PD could result
from a slowing of the neurodegeneration process in
the symptomatic phase similar to that seen in AD.32
This underlines the need for more specific progression
marker candidates for the early phase of the disease,
which will emerge from this and other ongoing studies.33
We explored many obvious candidates in a large
cohort of PD participants and looked for progression
markers for future use in clinical trial cohorts and
tried to exclude noninformative ones. The fact that
we identified no more than 33% of the markers ana-
lyzed having significantly changed during our 24-
month observational period highlights the mandate
of finding reliable progression markers. These results
have immediate consequences for clinical research in
PD by restricting the potential usage of some
markers, and will take more time to eventually change
the clinical care delivered to patients with PD.
There are limitations of clinical practice–led
exploratory studies, such as ours, which merit discus-
sion. First, DeNoPa is a real-life observational survey
study. Therefore, we symptomatically treated pa-
tients’ motor symptoms. The effects of dopaminergic
treatment on NMS vary depending up on the under-
lying mechanisms; i.e., a symptom influenced by
dopaminergic deficit may respond positively to dopa-
minergic treatment (such as depression and NMS),24
whereas a non-dopamine-responsive symptom may
worsen with such treatment (such as daytime sleepi-
ness, especially in the early titration phase; further
discussion can be found in appendix e-1).27 There-
fore, we cannot remove any influence conferred by
therapy on our investigational markers, but purpose-
fully included 8 markers that are likely independent
of any introduced symptomatic therapy,34 such as
MRI volumetry and blood and CSF markers.
Second, most of our proposed marker candidates
showed promising results as early diagnostic markers,
which does not necessarily qualify them as progres-
sion markers. Further marker candidates specific for
progression of the disease need to be explored. Third,
we did not control for multiple testing. Although this
is an appropriate exploratory strategy for detecting
true changes in patients with PD (i.e., reducing type
II errors), it may lead to false-positive findings. How-
ever, the detection of 10 significant changes among
30 tested is clearly more than would be expected by
chance alone, thus corroborating the significance of
our results as a whole.35
The use of our proposed panel of outcome meas-
ures needs further validation before being used to rate
progression across centers. One limitation is the
responsiveness of depression and some NMS to ther-
apy,36 requiring new elaborated NMS scales. This
should be undertaken independently by multicenter
cohorts enrolling larger numbers of participants; this
is currently underway.33
Future studies need to investigate the validity of
these proposed markers, standardize the assessment
of nonmotor features, and identify more sensitive
and disease-specific marker candidates that reflect
underlying biological processes (such as propagation
Figure 3 Longitudinal changes in 1.5T volumetric MRI
Estimated means and 95% confidence intervals of voxel-based morphometry (VBM) in total
gray matter volume (GMV) (A) and hippocampal volume (HCV) (B) at baseline (BL) and 2-year
follow-up (24FU). Blue line represents healthy controls (HC); red line represents participants
with Parkinson disease (PD). *Significant change in PD vs HC (p, 0.05). (C) Example of gray
matter segmentation in 3 orthogonal cutplanes. For the analysis, native space maps were
summed to generate an absolute volume per class and subject. (D) Example of smoothed
gray matter maps (in Montreal Neurological Institute space) shown with the a priori defined
hippocampal analysis region overlaid in red. Within this region, themean average gray matter
probability was calculated yielding one average value of hippocampal gray matter per
subject.
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of a-syn pathology, inflammation, and neuronal
death). In this way, validated and improved markers
will be used as clinically meaningful endpoints of
progression that are essential in the development of
treatments for PD.
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MACRA Changes How Neurologists Are Paid
What Is MACRA, and Why Is It Necessary?
The Medicare Access and CHIP Reauthorization Act of 2015—MACRA—replaced the
Medicare Sustainable Growth Rate formula for calculating physician payments. The rapidly rising
costs of health care in the US are unsustainable. Changes in the health care system are essential and
must happen now.
How Will MACRA Affect Physician Payment?
Our health care system is moving from “fee-for-service” payments to a wider array of “value-based”
payment models that put the patient at the center of care by calling for the improvement of the
quality, safety, and overall experience of patient care while demonstrating cost-effectiveness by
providing care that is less expensive and delivers similar or improved clinical outcomes.
Learn more at AAN.com/view/MACRA.
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